We created an inflammation-induced Parkinson's disease model, where microglia activation leads to oxidative stress, mitochondrial dysfunction, and dopaminergic neurodegeneration in the substantia nigra. Pioglitazone, an agonist of peroxisome proliferator activated receptor-gamma (PPAR-γ), can prevent these deficits and protect dopaminergic neurons. To continue exploring the effects of pioglitazone in this model we focused on the expression of PPAR-γ, uncoupling protein 2 (UCP2), and mitoNEET. We report that intrastriatal lipopolysaccharide (LPS) increases striatal PPAR-γ, UCP2, and mitoNEET expression, and pioglitazone attenuates these LPS-induced changes.
|Number of pages||4|
|State||Published - Feb 27 2008|
- Parkinson's disease
ASJC Scopus subject areas
- Neuroscience (all)